Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P15088 (
mast cell
)
14,925
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The ability of cyclosporine (
CSA
) and FK506 to inhibit cytokine production by factor-dependent murine
mast cell
lines was investigated. The
mast cell
clone, MC/9, and two
mast cell
lines, MCIII and MCVI, were stimulated to produce cytokines with phorbol myristate acetate plus the calcium ionophore A23187. The production of cytokines by stimulated mast cells cultured in the presence or absence of drug was monitored by bioassay of culture supernatants for induction of proliferation by factor-dependent cell lines and inhibition of these responses by neutralizing monoclonal antibodies. Both
CSA
and FK506 inhibited
mast cell
cytokine production at concentrations comparable to those observed with T cells. However, the degree of inhibition of cytokine production varied among the
mast cell
lines as well as between different cytokines produced by a given
mast cell
line. For example,
CSA
completely inhibited interleukin-2 (IL-2), IL-3, IL-4 and granulocyte-macrophage colony stimulating factor secretion by all three lines, with the exception that IL-2/IL-4 production by MCIII was partially resistant to inhibition by
CSA
. Similarly, FK506 completely inhibited cytokine production by MC/9, partially inhibited cytokine production by MCIII and had differential effects on IL-3/granulocyte-macrophage colony-stimulating factor and IL-2/IL-4 production by MCVI. Consistent with their ability to selectively inhibit cytokine gene transcription in T cells, neither
CSA
nor FK506 inhibited factor-dependent proliferation by these
mast cell
lines. In view of the putative role of cytokines in inflammation and late phase asthmatic reactions, these observations may be of particular significance in development of methods of pharmacologic intervention.
...
PMID:Cyclosporine and FK506 inhibition of murine mast cell cytokine production. 137 Nov 58
We have previously demonstrated that cyclosporine (
CSA
) and FK506 are able to selectively inhibit cytokine production by murine
mast cell
lines at concentrations comparable to those observed with thymus-derived lymphocytes (T cells). The selectivity of these effects were demonstrated by the failure of
CSA
and FK506 to inhibit cytokine-induced
mast cell
proliferation at equivalent or higher concentrations. In this report, we examined the ability of rapamycin (RAP) to inhibit cytokine production and cytokine-induced proliferation by a factor-dependent murine
mast cell
line and compared its activity to that of the structurally related macrolide FK506. The
mast cell
clone, MC/9, was stimulated to produce cytokines with phorbol myristate acetate plus the calcium ionophore A23187, or to proliferate in response to exogenous cytokines such as interleukin-3 and interleukin-4, produced by the helper T cell clone D10.G4. RAP did not inhibit cytokine production by MC/9, even at concentrations greater than 1000 nM. FK506 and
CSA
inhibited cytokine production with IC50 of 0.8 and 16.2 nM, respectively. In contrast to its lack of effect on cytokine production, RAP potently inhibited cytokine-induced proliferation of MC/9 cells with an IC50 of 1.9 nM. Because RAP and FK506 are structurally related and yet have divergent biological effects, we examined the ability of RAP to antagonize inhibitory effects of FK506 on
mast cell
cytokine production and the ability of FK506 to antagonize inhibitory effects of RAP on cytokine-induced
mast cell
proliferation. The addition of RAP in molar excess reversed inhibition of
mast cell
cytokine production mediated by FK506, but not that of
CSA
.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. 137 61